


What is claimed is:

1. A compound of formula I as indicated below:



5 wherein

n is 0 or 1;

When X is nitrogen or oxygen, Y is nothing;

When Y is nitrogen or oxygen, X is nothing;

T is a sulfonyl group (SO₂) or carbonyl group (CO) ;

10 When T=CO, X is oxygen or nitrogen;

Z⁻ is selected from the group consisting of halo, CF₃COO⁻, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

R₁ is selected from the group consisting of C₁-C₈ branched or

unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, C₃-C₈ alkenyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C₁-C₃ lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C₁-C₈ alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, phenyl and phenyl C₁-C₃ lower alkyl.

20 R₂ is selected from the group consisting of C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C₁-C₃ lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C₁-C₈ alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl and C₃-C₈ cycloalkyl lower alkyl and heterocycle rings;

R3 is selected from the group consisting of an unsubstituted or substituted following group: phenyl, phenyl C1-C6 lower alkyl, thiophenyl, thiophenyl C1-C6 lower alkyl, furanyl, furanyl C1-C6 lower alkyl, pyridinyl, pyridinyl C1-C6 lower alkyl, imidazolyl, imidazolyl C1-C6 lower alkyl, naphthyl, naphthyl C1-C6 lower alkyl, quinolinyl, quinolinyl C1-C6 lower alkyl, indolyl, indolyl C1-C6 lower alkyl, benzothiophenyl, benzothiophenyl C1-C6 lower alkyl, benzofuranyl, benzofuranyl C1-C6 lower alkyl, benzoimidazolyl, benzoimidazolyl C1-C6 lower alkyl, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl C₁-C₆ lower alkyl, or C₃-C₈ alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C₁-C₈ alkoxy, phenoxy, phenyl C₁-C₃ alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, phenyl, phenyl C1-C3 lower alkyl, thiophenyl, thiophenyl C1-C3 lower alkyl, furanyl, furanyl C1-C3 lower alkyl, pyridinyl, pyridinyl C1-C3 lower alkyl, naphthyl, naphthyl C1-C3 lower alkyl, quinolinyl, quinolinyl C1-C3 lower alkyl, indolyl, indolyl C1-C3 lower alkyl, benzothiophenyl, benzothiophenyl C1-C3 lower alkyl, benzofuranyl, benzofuranyl C1-C3 lower alkyl, COOH, COR₆, COOR₆, CONHR₆, CON(R₆)₂, COG, NHR₆, N(R₆)₂, G, OCOR₆, OCONHR₆, NHCOR₆, N(R₆)COR₆, NHCOOR₆ and NHCONHR₆;

R4 is selected from the group consisting of C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl.

25

2. A. compound according to claim 1 selected from the group consisting of:
 - n is 0 or 1;
 - When X is nitrogen or oxygen, Y is nothing;
 - When Y is nitrogen or oxygen, X is nothing;
 - T is a sulfonyl group (SO₂) or carbonyl group (CO) ;

30

When T=CO, X is oxygen or nitrogen;

Z⁻ is selected from the group consisting of halo, CF₃COO⁻, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;

R₁ is selected from the group consisting of C₁-C₈ branched or
5 unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, C₃-C₈
alkenyl, unsubstituted or substituted phenyl, or unsubstituted or substituted
phenyl C₁-C₃ lower alkyl; wherein, when substituted, a group is substituted by
one or more radicals selected from the group consisting of C₁-C₈ alkoxy, halo,
hydroxy, amino, cyano, trifluoromethyl, C₁-C₈ branched or unbranched alkyl,
10 C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, phenyl and phenyl C₁-C₃ lower
alkyl.

R₂ is selected from the group consisting of C₁-C₈ branched or
unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, unsubstituted
or substituted phenyl, or unsubstituted or substituted phenyl C₁-C₃ lower alkyl;
15 wherein, when substituted, a group is substituted by one or more radicals
selected from the group consisting of C₁-C₈ alkoxy, halo, hydroxy, amino,
cyano, trifluoromethyl, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl
and C₃-C₈ cycloalkyl lower alkyl and heterocycle rings;

R₃ is selected from the group consisting of an unsubstituted or
20 substituted following group: phenyl, phenyl C₁-C₆ lower alkyl, thiophenyl,
thiophenyl C₁-C₆ lower alkyl, furanyl, furanyl C₁-C₆ lower alkyl, pyridinyl,
pyridinyl C₁-C₆ lower alkyl, imidazolyl, imidazolyl C₁-C₆ lower alkyl, naphthyl,
naphthyl C₁-C₆ lower alkyl, quinolinyl, quinolinyl C₁-C₆ lower alkyl, indolyl,
indolyl C₁-C₆ lower alkyl, benzothiophenyl, benzothiophenyl C₁-C₆ lower alkyl,
25 benzofuranyl, benzofuranyl C₁-C₆ lower alkyl, benzoimidazolyl,
benzoimidazolyl C₁-C₆ lower alkyl, C₁-C₈ branched or unbranched alkyl, C₃-
C₈ cycloalkyl, C₃-C₈ cycloalkyl C₁-C₆ lower alkyl, or C₃-C₈ alkenyl; wherein,
when substituted, a group is substituted by one or more radicals selected from
the group consisting of C₁-C₈ alkoxy, phenoxy, phenyl C₁-C₃ alkoxy, halo,
30 hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy,

- propylenedioxy, butylenedioxy, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, phenyl, phenyl C₁-C₃ lower alkyl, thiophenyl, thiophenyl C₁-C₃ lower alkyl, furanyl, furanyl C₁-C₃ lower alkyl, pyridinyl, pyridinyl C₁-C₃ lower alkyl, naphthyl, naphthyl C₁-C₃ lower alkyl, 5 quinolinyl, quinolinyl C₁-C₃ lower alkyl, indolyl, indolyl C₁-C₃ lower alkyl, benzothiophenyl, benzothiophenyl C₁-C₃ lower alkyl, benzofuranyl, benzofuranyl C₁-C₃ lower alkyl, COOH, COR₆, COOR₆, CONHR₆, CON(R₆)₂, COG, NHR₆, N(R₆)₂, G, OCOR₆, OCONHR₆, NHCOR₆, N(R₆)COR₆, NHCOOR₆ and NHCONHR₆;
- 10 R₄ is selected from the group consisting of C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl.

or a pharmaceutically acceptable salt thereof.

- 15 3. A. compound according to claim 1 selected from the group consisting of:
- n is 0 or 1;
- When X is nitrogen or oxygen, Y is nothing;
- When Y is nitrogen or oxygen, X is nothing;
- 20 T is a sulfonyl group (SO₂) or carbonyl group (CO) ;
- When T=CO, X is oxygen or nitrogen;
- Z⁻ is selected from the group consisting of halo, CF₃COO⁻, mesylate, tosylate, or any other pharmaceutically acceptable counter ion;
- R₁ is selected from the group consisting of C₁-C₈ branched or
- 25 unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, C₃-C₈ alkenyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C₁-C₃ lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C₁-C₈ alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C₁-C₈ branched or unbranched alkyl,
- 30 C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, phenyl and phenyl C₁-C₃ lower alkyl.

R2 is selected from the group consisting of C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted phenyl C₁-C₃ lower alkyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C₁-C₈ alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl and C₃-C₈ cycloalkyl lower alkyl and heterocycle rings;

R3 is selected from the group consisting of an unsubstituted or substituted following group: phenyl, phenyl C₁-C₆ lower alkyl, thiophenyl, thiophenyl C₁-C₆ lower alkyl, furanyl, furanyl C₁-C₆ lower alkyl, pyridinyl, pyridinyl C₁-C₆ lower alkyl, imidazolyl, imidazolyl C₁-C₆ lower alkyl, naphthyl, naphthyl C₁-C₆ lower alkyl, quinolinyl, quinolinyl C₁-C₆ lower alkyl, indolyl, indolyl C₁-C₆ lower alkyl, benzothiophenyl, benzothiophenyl C₁-C₆ lower alkyl, benzofuranyl, benzofuranyl C₁-C₆ lower alkyl, benzoimidazolyl, benzoimidazolyl C₁-C₆ lower alkyl, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl C₁-C₆ lower alkyl, or C₃-C₈ alkenyl; wherein, when substituted, a group is substituted by one or more radicals selected from the group consisting of C₁-C₈ alkoxy, phenoxy, phenyl C₁-C₃ alkoxy, halo, hydroxy, amino, cyano, trifluoromethyl, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl, phenyl, phenyl C₁-C₃ lower alkyl, thiophenyl, thiophenyl C₁-C₃ lower alkyl, furanyl, furanyl C₁-C₃ lower alkyl, pyridinyl, pyridinyl C₁-C₃ lower alkyl, naphthyl, naphthyl C₁-C₃ lower alkyl, quinolinyl, quinolinyl C₁-C₃ lower alkyl, indolyl, indolyl C₁-C₃ lower alkyl, benzothiophenyl, benzothiophenyl C₁-C₃ lower alkyl, benzofuranyl, benzofuranyl C₁-C₃ lower alkyl, COOH, COR₆, COOR₆, CONHR₆, CON(R₆)₂, COG, NHR₆, N(R₆)₂, G, OCOR₆, OCONHR₆, NHCOR₆, N(R₆)COR₆, NHCOOR₆ and NHCONHR₆;

R4 is selected from the group consisting of C₁-C₈ branched or unbranched alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkyl lower alkyl.

4.

or a pharmaceutically acceptable salt thereof.

4. A. compound according to claim 1 selected from the group consisting of:
- 5 *N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {[(2,2,2-trifluoroethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {[(5-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 10 trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {[(4-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 15 {[(8-quinoliny)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {[(3,4-bis(methyloxy)phenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-
 tyrosinamide trifluoroacetate;
- 20 *N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {[(2-bromophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {[(4-fluorophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 25 trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 [(phenylsulfonyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {[(5-bromo-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 30 trifluoroacetate;
- N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 [(3-thienylsulfonyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(2,2,2-trifluoroethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(5-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(4-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(5-chloro-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(4-{(methylsulfonyl)oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(4-{(propylsulfonyl)oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{[(4-{[(2-(acetylamino)-4-methyl-1,3-thiazol-5-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(4-{(phenylsulfonyl)-2-thienyl]sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(5-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(2-naphthalenylsulfonyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

- N*-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-{[(2,2,2-trifluoroethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 5 *N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(5-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(4-methyl-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{[(4-{[(4-cyanophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;
- 10 *N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(4-(trifluoromethyl)phenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(5-(3-isoxazolyl)-2-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
- 15 trifluoroacetate;
- N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(3-fluorophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(1,3,5-trimethyl-1*H*-pyrazol-4-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
- 20 trifluoroacetate;
- N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(5-methyl-4-isoxazolyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 25 *N*-{[(4-{[(3,5-dimethyl-4-isoxazolyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;
- N*-{[(4-{[(2,4-dichlorophenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;
- 30 *N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-{[(4-(trifluoromethyl)oxy]phenyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;

- N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(1-methyl-1*H*-imidazol-4-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{[(4-[(cyclohexylcarbonyl)oxy]phenyl)amino]carbonyl}-*N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide trifluoroacetate;
- 5 *N*-{(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(cyclohexylcarbonyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(cyclohexylcarbonyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 10 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(cyclohexylcarbonyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 15 *N*-{(3*S*)-1-[[3,4-bis(methoxy)phenyl]methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(cyclohexylcarbonyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(2-methylpropanoyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 20 *N*-{(3*S*)-1-[(3-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(2-methylpropanoyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-[(4-chlorophenyl)methyl]-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(2-methylpropanoyl)oxy]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- N*-{(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]sulfonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 25 *N*-{(3*S*)-1-ethyl-1-[(3-hydroxyphenyl)methyl]-3-pyrrolidiniumyl}-*N*-{[(4-[(1-methylethyl)amino]sulfonyl]phenyl)amino]carbonyl}-L-tyrosinamide trifluoroacetate;
- 30 or any other pharmaceutically acceptable salt.

5. A compound according to claim 1 selected from the group consisting of:
N-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate
- 5 *N*-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate;
N-((3*S*)-1-[[3,4-bis(methyloxy)phenyl]methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-
 {(1-methylethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
- 10 trifluoroacetate;
N-[(3*S*)-1-(1,3-benzodioxol-5-ylmethyl)-1-methyl-3-piperidiniumyl]-*N*-{[(4-
 {(6-chloro-3-methyl-1-benzothien-2-yl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-
 tyrosinamide trifluoroacetate;
N-{[(4-[(2,5-dimethyl-3-thienyl)sulfonyl]oxy}phenyl)amino]carbonyl}-*N*-{(3*S*)-1-
 15 [(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl}-L-tyrosinamide
 trifluoroacetate;
N-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-[(1-
 methylethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate;
- 20 *N*-{(3*S*)-1-[(4-fluorophenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-[(1-
 methylethyl)sulfonyl]oxy}phenyl)amino]carbonyl}-L-tyrosinamide
 trifluoroacetate;
N-{(3*S*)-1-[(3-hydroxyphenyl)methyl]-1-methyl-3-piperidiniumyl)-*N*-{[(4-[(1-
 methylethyl)amino]sulfonyl]phenyl)amino]carbonyl}-L-tyrosinamide
- 25 trifluoroacetate

or any other pharmaceutically acceptable salt, or non-salt form thereof.

6. A Pharmaceutical composition for the treatment of muscarinic
 acetylcholine receptor mediated diseases comprising a compound according to
 30 claim 1 and a pharmaceutically acceptable carrier thereof.

7. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.
- 5 8. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.
9. A method according to claim 8 wherein the disease is selected from the
10 group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
10. A method according to claim 9 wherein administration is via inhalation
15 via the mouth or nose.
11. A method according to claim 10 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
- 20 12. A method according to claim 11 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.
13. A method according to claim 12 wherein the compound has a duration of
25 action of 24 hours or more.
14. A method according to claim 13 wherein the compound has a duration of action of 36 hours or more.